拓展液体活检的临床应用指征：疑似肺癌患者血浆的二代测序 - Suppr

Suppr

超能文献

Extending the clinical indications of liquid biopsy: plasma next-generation sequencing in suspected lung cancer.

作者信息

Russo Alessandro, Rolfo Christian, Santos Edgardo S

机构信息

Medical Oncology Department, Humanitas Instituto Clinico Catanese, Misterbianco, Catania, Italy.

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

出版信息

Transl Lung Cancer Res. 2025 Aug 31;14(8):2900-2905. doi: 10.21037/tlcr-2025-443. Epub 2025 Aug 14.

DOI:10.21037/tlcr-2025-443

PMID:40948828

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12432645/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce03/12432645/9b17d785adee/tlcr-14-08-2900-f1.jpg

相似文献

Extending the clinical indications of liquid biopsy: plasma next-generation sequencing in suspected lung cancer.拓展液体活检的临床应用指征：疑似肺癌患者血浆的二代测序

Transl Lung Cancer Res. 2025 Aug 31;14(8):2900-2905. doi: 10.21037/tlcr-2025-443. Epub 2025 Aug 14.

Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.液体活检能否通过低深度全基因组测序检测肉瘤患者的循环肿瘤DNA？一项初步评估。

Clin Orthop Relat Res. 2025 Jan 1;483(1):39-48. doi: 10.1097/CORR.0000000000003161. Epub 2024 Jun 21.

Clinical Utility of ctDNA Analysis in Lung Cancer-A Review.循环肿瘤DNA分析在肺癌中的临床应用——综述

Adv Respir Med. 2025 Jun 12;93(3):17. doi: 10.3390/arm93030017.

Impact of Higher Cell-Free DNA Yields on Liquid Biopsy Testing in Glioblastoma Patients.更高的游离DNA产量对胶质母细胞瘤患者液体活检检测的影响

Clin Chem. 2025 Jan 3;71(1):215-225. doi: 10.1093/clinchem/hvae178.

Standardized Workflow and Analytical Validation of Cell-Free DNA Extraction for Liquid Biopsy Using a Magnetic Bead-Based Cartridge System.使用基于磁珠的试剂盒系统进行液体活检游离DNA提取的标准化工作流程及分析验证

Cells. 2025 Jul 11;14(14):1062. doi: 10.3390/cells14141062.

Preoperative ctDNA retains prognostic relevance beyond postoperative assessment in stage II-III colon cancer.在II-III期结肠癌中，术前循环肿瘤DNA（ctDNA）在术后评估之外仍具有预后相关性。

Clin Exp Med. 2025 Jun 30;25(1):222. doi: 10.1007/s10238-025-01762-4.

Clinical utility of liquid biopsy next-generation sequencing for advanced non-small cell lung cancer in the Netherlands.荷兰晚期非小细胞肺癌液体活检下一代测序的临床应用价值

Sci Rep. 2025 Aug 19;15(1):30343. doi: 10.1038/s41598-025-13667-z.

Monitoring pembrolizumab response in patients with metastatic non-small cell lung cancer using circulating tumour DNA and circulating tumour cells.利用循环肿瘤DNA和循环肿瘤细胞监测转移性非小细胞肺癌患者的帕博利珠单抗反应。

Transl Lung Cancer Res. 2025 Jun 30;14(6):1945-1960. doi: 10.21037/tlcr-2024-1095. Epub 2025 Jun 26.

Detecting actionable mutations from matched plasma-based versus tissue next-generation sequencing in advanced non-small cell lung cancer: a retrospective single centre analysis on site.在晚期非小细胞肺癌中，比较基于血浆与组织的二代测序检测可 actionable 突变：一项单中心现场回顾性分析

J Exp Clin Cancer Res. 2025 Aug 6;44(1):229. doi: 10.1186/s13046-025-03480-x.

Prospective Multicenter Study Evaluating a Combined Circulating Tumor DNA and Circulating Tumor RNA Liquid Biopsy in Metastatic Non-Small Cell Lung Cancer (LIQUIK).评估循环肿瘤DNA与循环肿瘤RNA联合液体活检在转移性非小细胞肺癌中的前瞻性多中心研究（LIQUIK）

JCO Precis Oncol. 2025 Jun;9:e2500181. doi: 10.1200/PO-25-00181. Epub 2025 Jun 26.

本文引用的文献

LIBELULE: A Randomized Phase III Study to Evaluate the Clinical Relevance of Early Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer.LIBELULE：一项评估早期液体活检对可疑转移性肺癌患者临床相关性的随机III期研究。

J Thorac Oncol. 2025 Apr;20(4):437-450. doi: 10.1016/j.jtho.2024.12.011. Epub 2024 Dec 16.

Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation.ctDNA 肿瘤分数测量可识别有意义的阴性液体活检结果，并为组织确认的价值提供信息。

Clin Cancer Res. 2024 Jun 3;30(11):2452-2460. doi: 10.1158/1078-0432.CCR-23-3321.

The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer.既往单基因检测对非小细胞肺癌患者综合基因组分析结果的影响

Oncol Ther. 2024 Jun;12(2):329-343. doi: 10.1007/s40487-024-00270-x. Epub 2024 Mar 19.

Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment.在病理诊断前进行肺癌液体活检与更短的治疗时间相关。

JCO Precis Oncol. 2024 Jan;8:e2300535. doi: 10.1200/PO.23.00535.

Upfront liquid next-generation sequencing in treatment-naïve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system.初治晚期非小细胞肺癌患者的一线液体下一代测序：台湾医疗体系中的一项前瞻性随机研究。

Eur J Cancer. 2023 Nov;193:113310. doi: 10.1016/j.ejca.2023.113310. Epub 2023 Aug 28.

Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.分子基因分型结果的可获得性与晚期非鳞状非小细胞肺癌患者总生存期的关系。

JCO Precis Oncol. 2023 Jul;7:e2300191. doi: 10.1200/PO.23.00191.

Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung Cancer: The ACCELERATE Nonrandomized Clinical Trial.在疑似晚期肺癌患者中，组织诊断前进行循环肿瘤 DNA 检测与治疗时间的关联：ACCELERATE 非随机临床试验。

JAMA Netw Open. 2023 Jul 3;6(7):e2325332. doi: 10.1001/jamanetworkopen.2023.25332.

Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC).液体活检与组织活检在确定转移性非小细胞肺癌（NSCLC）一线治疗中的比较。

Clin Lung Cancer. 2023 Mar;24(2):120-129. doi: 10.1016/j.cllc.2022.11.007. Epub 2022 Nov 25.

Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC.基于组织和血液的综合基因组分析在检测晚期非小细胞肺癌可操作驱动改变中的互补作用

JTO Clin Res Rep. 2022 Aug 2;3(9):100386. doi: 10.1016/j.jtocrr.2022.100386. eCollection 2022 Sep.

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.ESMO 关于使用循环肿瘤 DNA 检测用于癌症患者的建议：来自 ESMO 精准医学工作组的报告。

Ann Oncol. 2022 Aug;33(8):750-768. doi: 10.1016/j.annonc.2022.05.520. Epub 2022 Jul 6.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验